References
Unsupervised principal component analysis of 57 significantly different metabolites between lifestyle intervention and surgery group in the WAS cohort at 1-year follow-up. The first component explains 32% of the variation, and the second component 17%. C, acylcarnitine; lysoPC, lysophosphatidylcholine; PC aa, phosphatidylcholine with ester bonding; PC ae phosphatidylcholine with ether bonding; SM, sphingolipid.Heat map showing the scaled relative abundance of metabolites, which were significantly different between LS and OP group at one-year follow-up, visualized by hierarchical clustering. Abundance values represent row-wise z-scores of read counts. Each bar in the horizontal columns (which represent different patients) represents the expression intensity. Blue indicates a decreased level, red indicates an increased level. C, acylcarnitine; lysoPC, lysophosphatidylcholine; PC aa, phosphatidylcholine with ester bonding; PC ae phosphatidylcholine with ether bonding; SM, sphingolipid.Unsupervised principal component analysis of significantly different metabolites (n = 62) between BWM and RYGB rats. The first component explains 52% of the variation, and the second component 22%. C, acylcarnitine; lysoPC, lysophosphatidylcholine; PC aa, phosphatidylcholine with ester bonding; PC ae phosphatidylcholine with ether bonding; SM, sphingolipid.Heat map with the scaled relative abundance of 62 significantly different metabolites in BWM and RYGB rats four weeks postoperative visualized by metabolite hierarchical clustering. Abundance values represent row-wise z-scores of read counts. Each bar in the horizontal columns (which represent different rats) represents the expression intensity. Blue indicates a decreased level, red indicates an increased level. C, acylcarnitine; lysoPC, lysophosphatidylcholine; PC aa, phosphatidylcholine with ester bonding; PC ae phosphatidylcholine with ether bonding; SM, sphingolipid.Metabolomic profile of 57 significantly different metabolites of acylcarnitines; amino acids; lysophosphatidylcholines; sphingolipids; acylcarnitines; biogenic amines; phosphatidylcholines with ester bonding; phosphatidylcholines with ether bonding; hexose, between lifestyle (LS) and RYGB (OP) group at one-year follow-up.Metabolomic profile of 62 significantly different parameters of amino acids; lysophosphatidylcholines; sphingolipids; acylcarnitines; phosphatidylcholines with ester bonding; phosphatidylcholines with ether bonding, between rats with RYGB and rats with diet restriction (BWM) four weeks after start of the interventions.Time schedule of the WAS trial. R, randomization.Medians ± interquartile range (IQR) of baseline characteristics with standard deviation of patients enrolled in the WAS trial.One-year follow-up means of 57 significantly different metabolites between LS and OP with standard deviation. Means of 62 significantly different metabolites at four weeks after start of the interventions between BWM_rat and RYGB_rat with standard deviation. Eighty-one significantly different metabolites subsequently in LS vs. OP of the WAS cohort at one-year follow-up and in animals treated with RYGB vs. diet-restricted animals of the rat cohort four weeks after start of the interventions. Thirty-one overlapping metabolites found to be significant in both comparisons are printed in bold. Arrows indicate if the metabolite is increased or decreased in the respective surgical group in comparison the conservative group. C, acylcarnitine; lysoPC, lysophosphatidylcholine; PC aa, phosphatidylcholine with ester bonding; PC ae phosphatidylcholine with ether bonding; SM, sphingolipid.